These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6130864)

  • 1. Alpha-adrenoceptor blockade by labetalol during long-term dosing.
    Semplicini A; Pessina AC; Rossi GP; Hlede M; Morandin F
    Clin Pharmacol Ther; 1983 Mar; 33(3):278-82. PubMed ID: 6130864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological basis for antihypertensive effects of intravenous labetalol.
    Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
    Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
    Honda K; Takenaka T; Shiono K; Miyata-Osawa A; Nakagawa C
    Jpn J Pharmacol; 1985 May; 38(1):31-41. PubMed ID: 2862302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
    Richards DA; Tuckman J; Prichard BN
    Br J Clin Pharmacol; 1976 Oct; 3(5):849-55. PubMed ID: 9968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
    Drew GM; Hilditch A; Levy GP
    Clin Exp Hypertens (1978); 1979; 1(5):597-611. PubMed ID: 42517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.
    Riva E; Mennini T; Latini R
    Br J Pharmacol; 1991 Dec; 104(4):823-8. PubMed ID: 1687367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man.
    Riddell JG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1985 Apr; 19(4):405-10. PubMed ID: 2859871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of combined alpha-beta-blockade. I.
    Louis WJ; McNeil JJ; Drummer OH
    Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment.
    Sanders GL; Murray A; Rawlins MD
    Br J Clin Pharmacol; 1979; 8(Suppl 2):125S-127S. PubMed ID: 43163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats.
    Inagaki O; Sudoh K; Shibasaki M; Nakagawa C; Honda K
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):794-802. PubMed ID: 7532758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent antagonism of isoproterenol and norepinephrine after labetalol.
    Richards DA; Prichard BN
    Clin Pharmacol Ther; 1978 Mar; 23(3):253-8. PubMed ID: 627129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade.
    Koch G
    J Cardiovasc Pharmacol; 1981; 3 Suppl 1():S30-41. PubMed ID: 6169958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.